Atrial Fibrillation Cycle Length Measured on Transesophageal Echocardiography

Last updated: April 5, 2018
Sponsor: Pusan National University Yangsan Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Cardiac Disease

Dysrhythmia

Atrial Fibrillation

Treatment

N/A

Clinical Study ID

NCT03496272
PNUYH-IRB-05-2016-154
  • Ages > 18
  • All Genders

Study Summary

Background: The atrial fibrillation cycle length (AFCL) measured by electrophysiologic study is well known parameter for the maintenance of sinus rhythm after DC cardioversion (DCCV) or ablation therapy. The aim of this study was to test whether a AFCL measured by transesophageal echocardiography (AFCLTEE) could predict the outcome after DCCV.

Methods: In 100 consecutive patients with non-valvular AF, TEE will be performed within 6 hours before DCCV. The AFCLTEE was measured by averaging 10 sequential peak to peak intervals of atrial fibrillary waves seen in the pulsed wave Doppler image on the left atrial appendage. The primary endpoint was AF free survival rate at 6 months after DCCV.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • atrial fibrillation

Exclusion

Exclusion Criteria:

  • moderate or severe mitral stenosis

  • prosthetic heart valve

Study Design

Total Participants: 100
Study Start date:
January 01, 2017
Estimated Completion Date:
June 30, 2021

Connect with a study center

  • Pusan National University Yangsan Hospital

    Yangsan, 50612
    Korea, Republic of

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.